Soon after University of Oxford and AstraZeneca PLC’s announcement that their COVID-19 vaccine AZD1222 showed 70% efficacy in interim results from Phase III trials, their Indian partner, Serum Institute of India Pvt. Ltd., revealed that it also cut virus spread by 60%.
In the global study conducted by the UK partners, “There were zero hospitalizations in the vaccinated group and the vaccine also brought down by 60% spreading of the virus. So, it grants sterilizing immunity as well and the vaccinated group does not infect others
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?